ACOR

Acorda Therapeutics, Inc. (ACOR) | Rumor.io

Acorda Therapeutics

ACOR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ACOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Apr 9

$ACOR is a high-risk play with a potential delisting squeeze due to its low float of 1.2M shares and recent drop from $18.
The company's delisting on Friday, April 12th, 2024, may trigger a significant price run before the delisting, given its heavily shorted status.
$ACOR's trading volume has been above average, with 170% above average volume on one day and 33% above average volume on another, indicating increased market interest in the stock.

Generated by AI

Sentiment

Of the messages about ACOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Oct 31

$ACOR has seen a 144% increase, making it a multibagger opportunity with fresh multi-year guidance.
The stock has shown impressive strength, rising 74% without halting, and has a high potential for further growth.
The float rotation of $ACOR has led to elevated squeeze potential, with a gain of 5.3% and a short float of 3.3%, indicating a promising short-term outlook.

Bearish· Jul 23

$ACOR's bounce was rejected, leading to a significant decline.
The stock's attempt to bounce off support is losing momentum, and a drop below $4.70 could lead to further weakness.
$ACOR's technicals are not holding up, and the stock is at risk of declining to the mid-$5s or lower.

Generated by AI

Topics

Of the messages about ACOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· May 2

Acorda Therapeutics, Inc. ($ACOR) reported FQ1 earnings of 14c EPS and $106.17M in revenues.
$ACOR missed EPS estimates by $0.33 and also fell short on revenues.
This earnings report marks a disappointing quarter for Acorda Therapeutics, Inc.

Analysts· Nov 16

Stifel downgraded ACOR to hold with a $15 price target from $26.
Raymond James and ValuEngine downgraded ACOR to underperform and sell, respectively.
Leerink Swann lowered ACOR's price target to $18, and ValuEngine downgraded the company to sell with a $19 price target.

Announcements· Apr 3

Acorda Therapeutics, Inc. (ACOR) has received approval news from Biopas Laboratories for INBRIJA in six Latin American countries.
Biopas Laboratories has filed for approval of INBRIJA in six Latin American countries, with potential news dropping this week.
There is no other relevant information about ACOR in the provided posts.

Controversies· Oct 16

Acorda Therapeutics, Inc. ($ACOR) has been awarded $16.5M in an AMPYRA arbitration case, resolving royalty and supply issues.
The arbitration case involved disputes over AMPYRA royalties and supply agreements.
The settlement provides relief to Acorda Therapeutics, potentially alleviating financial pressures related to the AMPYRA franchise.

Generated by AI

Community

Of the messages about ACOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0%
Newcomers	—	—	—	100%

Regulars· Apr 3

The regulars are monitoring $ACOR's trend, noting it's still above its EMAs and could be due for a drop, having risen 9.1% so far.
The float for $ACOR is 1.2M and the short interest is 0.8%.
The trained model has predicted that $ACOR's stock price will not rise in the near future and may not present a long-term opportunity.

Newcomers· Apr 2

The company has filed for Chapter 11 bankruptcy protection, with plans to sell its assets to a US subsidiary of Germany's Merz for $185M, listing debts of $266M against $108.5M of assets.
The stock is down over 80% due to the bankruptcy filing, and some investors are speculating about the potential for a "bk bounce".
The CEO of Acorda Therapeutics has been criticized for not buying more of the company's stock on the market, despite making tens of millions of dollars as CEO.

Generated by AI

Also Discussed

Investors talking about ACOR also mention

#	Name	Attention
1	Socket Mobile Inc.SCKT	0%0
2	NBRV - Nabriva Therapeutics plc	——
3	NanoVibronix, Inc.NAOV	0%0
4	Alkermes plcALKS	0%0
5	THMO - ThermoGenesis Holdings, Inc.	——
6	Agios Pharmaceuticals, Inc.AGIO	0%0
7	AXDX - Accelerate Diagnostics, Inc.	——
8	BPTS - Biophytis S.A.	——
9	AcelRx Pharmaceuticals IncACRX	0%new
10	HTBX - Heat Biologics, Inc.	——